FDA Approves Flowonix Maestro Software for Pump Programming

Article

The updated software will begin being implemented this month for use with the Prometra Pump System.

FDA,

The US Food and Drug Administration (FDA) has approved the marketing of Flowonix Maestro Software for Clinician Programmers. The new software is used to program Prometra Pump Systems.

Flowonix Maestro Software was designed to help both clinicians and patients by improving the user experience. It builds on the software currently used with Prometra Clinician Programmer. The Prometra Programmable Infusion Pump System is used for intrathecal delivery of drugs including Infumorph (preservative-free morphine sulfate sterile solution), saline solution, and baclofen.

"Physicians continue to be drawn to the Prometra System due to its ability to provide consistently accurate dosing using a novel micro-bolus delivery mechanism that delivers medication rapidly and broadly to the spinal cord," said Jason Poston, MD, an interventional pain physician in Idaho Falls, Idaho, in a statement. "The easy-to-use Flowonix Maestro Software will further simplify the process of introducing this pump technology into physicians' practices, and, more importantly, increase the opportunities for patients to benefit from it."

Improvements to the new software include automatic calculations, greater flexibility in dosing during bridge bolusing, enhancements to Periodic Flow and Multiple Rate Flow capabilities, and modifications to the programmer workflow designed to reduce complexity and ensure necessary steps are taken during programming.

The company plans to introduce and begin implementing the Flowonix Maestro Software this month.

"We are excited to introduce the Flowonix Maestro Software into clinics around the country, as the enhancements included in the software were driven by feedback provided directly by our customers," said Larry Heaton, President and CEO of Flowonix Medical, Inc, in a statement. "We are confident the combination of the Flowonix Maestro Software and the novel drug delivery mechanism of the Prometra Pump will strengthen our position in the marketplace and set the company up for long-term success in targeted drug delivery.

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
© 2024 MJH Life Sciences

All rights reserved.